Thromboprophylaxis in congenital nephrotic syndrome: 15-year experience from a national cohort.

ABSTRACT:

Introduction

Congenital nephrotic syndrome (CNS) is an ultra-rare disease associated with a pro-thrombotic state and venous thromboembolisms (VTE). There is very limited evidence evaluating thromboprophylaxis in patients with CNS. This study aimed to determine the doses and duration of treatment required to achieve adequate thromboprophylaxis in patients with CNS.

Methods

From 2005 to 2018 children in Scotland with a confirmed genetic or histological diagnosis of CNS were included if commenced on thromboprophylaxis. The primary study endpoint was stable drug monitoring. Secondary outcomes included VTE or significant haemorrhage.

Results

Eight patients were included; all initially were commenced on low-molecular weight heparin (enoxaparin). Four patients maintained the

SUBMITTER: Dobbie LJ 

PROVIDER: S-EPMC8009789 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature